Copyright
©2006 Baishideng Publishing Group Co.
World J Gastroenterol. Nov 21, 2006; 12(43): 6955-6960
Published online Nov 21, 2006. doi: 10.3748/wjg.v12.i43.6955
Published online Nov 21, 2006. doi: 10.3748/wjg.v12.i43.6955
Grade of severity (n) | Total | |||||
Adverse event | G1 | G2 | G3 | G4 | G5 | n (%) |
Constipation | 2 | 22 | 0 | 0 | 0 | 24 (57) |
Skin rash | 6 | 8 | 3 | 0 | 0 | 17 (41) |
Low leg edema | 1 | 10 | 0 | 0 | 0 | 11 (26) |
Dizziness | 3 | 5 | 1 | 0 | 0 | 9 (21) |
Lethargy | 3 | 2 | 2 | 0 | 0 | 7 (17) |
Nausea/vomiting | 1 | 5 | 0 | 0 | 0 | 6 (14) |
Neurosensory | 3 | 0 | 0 | 0 | 0 | 3 (7) |
Dyspnea | 0 | 2 | 0 | 0 | 0 | 2 (5) |
Leukopenia | 1 | 0 | 0 | 0 | 0 | 1 (2) |
Thrombocytopenic purpura | 0 | 1 | 0 | 0 | 0 | 1 (2) |
Insomnia | 0 | 1 | 0 | 0 | 0 | 1 (2) |
Alopecia | 1 | 0 | 0 | 0 | 0 | 1 (2) |
- Citation: Chiou HE, Wang TE, Wang YY, Liu HW. Efficacy and safety of thalidomide in patients with hepatocellular carcinoma. World J Gastroenterol 2006; 12(43): 6955-6960
- URL: https://www.wjgnet.com/1007-9327/full/v12/i43/6955.htm
- DOI: https://dx.doi.org/10.3748/wjg.v12.i43.6955